{"pmid":32292881,"pmcid":"PMC7146059","title":"Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.","text":["Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.","Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods.","Cell Stress","Raoult, Didier","Zumla, Alimuddin","Locatelli, Franco","Ippolito, Giuseppe","Kroemer, Guido","32292881"],"abstract":["Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods."],"journal":"Cell Stress","authors":["Raoult, Didier","Zumla, Alimuddin","Locatelli, Franco","Ippolito, Giuseppe","Kroemer, Guido"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292881","week":"202016|Apr 13 - Apr 19","doi":"10.15698/cst2020.04.216","keywords":["COVID-19","Coronavirus","MERS-CoV","SARS-CoV","epidemiology","immunology","sARS-CoV-2"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1664266295738105857,"score":8.233237,"similar":[{"pmid":32293743,"title":"Coinfection with COVID-19 and Coronavirus HKU1 - the critical need for repeat testing if clinically indicated.","text":["Coinfection with COVID-19 and Coronavirus HKU1 - the critical need for repeat testing if clinically indicated.","COVID-19 is the latest global pandemic caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2). There have been seven pathogenic Human Coronaviruses (HCoVs) which cause respiratory infections. Common cold coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 are the four endemic HCoVs. SARS-CoV-1, MERS-CoV, SARS-CoV-2 are zoonotic emerging epidemic pathogens with significant morbidity, mortality and economic impact. The endemic HCoVs have been known to cause co-infections or can be co-detected with each other or with other respiratory viruses. In general, respiratory viral co-infections are recognized more commonly today with the use of respiratory multiplex molecular diagnostic panels. Clinicians need to be aware of co-infections among HCoVs. A high degree of suspicion in this rapidly evolving outbreak is required in order to make the diagnosis. This is vital if we are to try and contain and control the spread of the COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Chaung, Jenna","Chan, Douglas","Pada, Surinder","Tambyah, Paul A","32293743"],"abstract":["COVID-19 is the latest global pandemic caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2). There have been seven pathogenic Human Coronaviruses (HCoVs) which cause respiratory infections. Common cold coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 are the four endemic HCoVs. SARS-CoV-1, MERS-CoV, SARS-CoV-2 are zoonotic emerging epidemic pathogens with significant morbidity, mortality and economic impact. The endemic HCoVs have been known to cause co-infections or can be co-detected with each other or with other respiratory viruses. In general, respiratory viral co-infections are recognized more commonly today with the use of respiratory multiplex molecular diagnostic panels. Clinicians need to be aware of co-infections among HCoVs. A high degree of suspicion in this rapidly evolving outbreak is required in order to make the diagnosis. This is vital if we are to try and contain and control the spread of the COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chaung, Jenna","Chan, Douglas","Pada, Surinder","Tambyah, Paul A"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293743","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25890","keywords":["Coronavirus","Infection","SARS coronavirus","Virus classification"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266295592353793,"score":335.94006},{"pmid":32293832,"title":"Coronaviruses and SARS-CoV-2.","text":["Coronaviruses and SARS-CoV-2.","Coronaviruses (CoVs) cause a broad spectrum of diseases in domestic and wild animals, poultry, and rodents, ranging from mild to severe enteric, respiratory, and systemic disease, and also cause the common cold or pneumonia in humans. Seven coronavirus species are known to cause human infection, four of which, HCoV 229E, HCoV NL63, HCoV HKU1 and HCoV OC43, typically cause cold symptoms in immunocompetent individuals. The others namely SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus) were zoonotic in origin and cause severe respiratory illness and fatalities. On 31 December 2019, the existence of patients with pneumonia of an unknown etiology were reported to WHO by the national authorities in China. This virus was officially identified by the Coronavirus Study Group as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the present outbreak of a coronavirus-associated acute respiratory disease was labeled coronavirus disease 19 (COVID-19). COVID-19 was seen for the first cases in Turkey on March 10, 2020 and was number 47,029 cases and 1,006 deaths after 1 month. Infections with SARS-CoV-2 are now widespread, and as of 10 April 2020, 1,727,602 cases have been confirmed in more than 210 countries, with 105,728 deaths.","Turk J Med Sci","Hasoksuz, Mustafa","Kilic, Selcuk","Sarac, Fahriye","32293832"],"abstract":["Coronaviruses (CoVs) cause a broad spectrum of diseases in domestic and wild animals, poultry, and rodents, ranging from mild to severe enteric, respiratory, and systemic disease, and also cause the common cold or pneumonia in humans. Seven coronavirus species are known to cause human infection, four of which, HCoV 229E, HCoV NL63, HCoV HKU1 and HCoV OC43, typically cause cold symptoms in immunocompetent individuals. The others namely SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus) were zoonotic in origin and cause severe respiratory illness and fatalities. On 31 December 2019, the existence of patients with pneumonia of an unknown etiology were reported to WHO by the national authorities in China. This virus was officially identified by the Coronavirus Study Group as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the present outbreak of a coronavirus-associated acute respiratory disease was labeled coronavirus disease 19 (COVID-19). COVID-19 was seen for the first cases in Turkey on March 10, 2020 and was number 47,029 cases and 1,006 deaths after 1 month. Infections with SARS-CoV-2 are now widespread, and as of 10 April 2020, 1,727,602 cases have been confirmed in more than 210 countries, with 105,728 deaths."],"journal":"Turk J Med Sci","authors":["Hasoksuz, Mustafa","Kilic, Selcuk","Sarac, Fahriye"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293832","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-127","keywords":["Animal coronaviruses","COVID-19","History of coronaviruses","Human Coronaviruses","SARS-CoV-2"],"source":"PubMed","weight":0,"locations":["China","Turkey"],"countries":["Turkey","China"],"countries_codes":["TUR|Turkey","CHN|China"],"_version_":1664266295588159488,"score":311.9914},{"pmid":32226286,"pmcid":"PMC7098031","title":"Zoonotic origins of human coronaviruses.","text":["Zoonotic origins of human coronaviruses.","Mutation and adaptation have driven the co-evolution of coronaviruses (CoVs) and their hosts, including human beings, for thousands of years. Before 2003, two human CoVs (HCoVs) were known to cause mild illness, such as common cold. The outbreaks of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) have flipped the coin to reveal how devastating and life-threatening an HCoV infection could be. The emergence of SARS-CoV-2 in central China at the end of 2019 has thrusted CoVs into the spotlight again and surprised us with its high transmissibility but reduced pathogenicity compared to its sister SARS-CoV. HCoV infection is a zoonosis and understanding the zoonotic origins of HCoVs would serve us well. Most HCoVs originated from bats where they are non-pathogenic. The intermediate reservoir hosts of some HCoVs are also known. Identifying the animal hosts has direct implications in the prevention of human diseases. Investigating CoV-host interactions in animals might also derive important insight on CoV pathogenesis in humans. In this review, we present an overview of the existing knowledge about the seven HCoVs, with a focus on the history of their discovery as well as their zoonotic origins and interspecies transmission. Importantly, we compare and contrast the different HCoVs from a perspective of virus evolution and genome recombination. The current CoV disease 2019 (COVID-19) epidemic is discussed in this context. In addition, the requirements for successful host switches and the implications of virus evolution on disease severity are also highlighted.","Int J Biol Sci","Ye, Zi-Wei","Yuan, Shuofeng","Yuen, Kit-San","Fung, Sin-Yee","Chan, Chi-Ping","Jin, Dong-Yan","32226286"],"abstract":["Mutation and adaptation have driven the co-evolution of coronaviruses (CoVs) and their hosts, including human beings, for thousands of years. Before 2003, two human CoVs (HCoVs) were known to cause mild illness, such as common cold. The outbreaks of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) have flipped the coin to reveal how devastating and life-threatening an HCoV infection could be. The emergence of SARS-CoV-2 in central China at the end of 2019 has thrusted CoVs into the spotlight again and surprised us with its high transmissibility but reduced pathogenicity compared to its sister SARS-CoV. HCoV infection is a zoonosis and understanding the zoonotic origins of HCoVs would serve us well. Most HCoVs originated from bats where they are non-pathogenic. The intermediate reservoir hosts of some HCoVs are also known. Identifying the animal hosts has direct implications in the prevention of human diseases. Investigating CoV-host interactions in animals might also derive important insight on CoV pathogenesis in humans. In this review, we present an overview of the existing knowledge about the seven HCoVs, with a focus on the history of their discovery as well as their zoonotic origins and interspecies transmission. Importantly, we compare and contrast the different HCoVs from a perspective of virus evolution and genome recombination. The current CoV disease 2019 (COVID-19) epidemic is discussed in this context. In addition, the requirements for successful host switches and the implications of virus evolution on disease severity are also highlighted."],"journal":"Int J Biol Sci","authors":["Ye, Zi-Wei","Yuan, Shuofeng","Yuen, Kit-San","Fung, Sin-Yee","Chan, Chi-Ping","Jin, Dong-Yan"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226286","week":"202014|Mar 30 - Apr 05","doi":"10.7150/ijbs.45472","keywords":["*COVID-19","*MERS-CoV","*SARS-CoV","*SARS-CoV-2","*animal reservoir","*bats","*coronavirus"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1663352135295696896,"score":263.9292},{"pmid":32252141,"title":"Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19).","text":["Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19).","A cluster of severe pneumonia of unknown etiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was isolated from lower respiratory tract sample as the causative agent. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 rapidly spread into at least 114 countries and killed more than 4,000 people by March 11 2020. WHO officially declared COVID-19 a pandemic on March 11, 2020. There have been two novel coronavirus outbreaks in the past two decades. The 2002-2003 outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 caused by SARS-CoV had a case fatality rate of around 10% (8,098 confirmed cases and 774 death), while Middle East respiratory syndrome (MERS) caused by MERS-CoV killed 861 people out of a total 2,502 confirmed cases between 2012 and 2019. The purpose of this review is to summarize known-to-date information about SARS-CoV-2, transmission of SARS-CoV-2, and clinical features.","Clin Exp Pediatr","Park, Su Eun","32252141"],"abstract":["A cluster of severe pneumonia of unknown etiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was isolated from lower respiratory tract sample as the causative agent. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 rapidly spread into at least 114 countries and killed more than 4,000 people by March 11 2020. WHO officially declared COVID-19 a pandemic on March 11, 2020. There have been two novel coronavirus outbreaks in the past two decades. The 2002-2003 outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 caused by SARS-CoV had a case fatality rate of around 10% (8,098 confirmed cases and 774 death), while Middle East respiratory syndrome (MERS) caused by MERS-CoV killed 861 people out of a total 2,502 confirmed cases between 2012 and 2019. The purpose of this review is to summarize known-to-date information about SARS-CoV-2, transmission of SARS-CoV-2, and clinical features."],"journal":"Clin Exp Pediatr","authors":["Park, Su Eun"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32252141","week":"202015|Apr 06 - Apr 12","doi":"10.3345/cep.2020.00493","keywords":["COVID-19","MERS-CoV","SARS-CoV","SARS-CoV-2","coronavirus"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Diagnosis"],"weight":1,"_version_":1663352136196423680,"score":238.23088},{"pmid":32265848,"pmcid":"PMC7105881","title":"Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.","text":["Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.","Seven coronaviruses (CoVs) have been isolated from humans so far. Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. 2019-nCoV was first reported from China in December 2019, and is currently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins, and the potential factors affecting these subunit vaccines are also illustrated. Overall, this review will be helpful for rapid design and development of vaccines against the new 2019-nCoV and any future CoVs with pandemic potential. This review was written for the topic of Antivirals for Emerging Viruses: Vaccines and Therapeutics in the Virology section of Frontiers in Microbiology.","Front Microbiol","Wang, Ning","Shang, Jian","Jiang, Shibo","Du, Lanying","32265848"],"abstract":["Seven coronaviruses (CoVs) have been isolated from humans so far. Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. 2019-nCoV was first reported from China in December 2019, and is currently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins, and the potential factors affecting these subunit vaccines are also illustrated. Overall, this review will be helpful for rapid design and development of vaccines against the new 2019-nCoV and any future CoVs with pandemic potential. This review was written for the topic of Antivirals for Emerging Viruses: Vaccines and Therapeutics in the Virology section of Frontiers in Microbiology."],"journal":"Front Microbiol","authors":["Wang, Ning","Shang, Jian","Jiang, Shibo","Du, Lanying"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265848","week":"202015|Apr 06 - Apr 12","doi":"10.3389/fmicb.2020.00298","keywords":["2019-nCoV","MERS-CoV","SARS-CoV","human coronaviruses","pathogenesis","subunit vaccines"],"source":"PubMed","locations":["Microbiology","Frontiers","Saudi Arabia","China"],"countries":["China","Saudi Arabia"],"countries_codes":["CHN|China","SAU|Saudi Arabia"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663609715796475904,"score":235.56758}]}